Roberts Richard, Williams David M, Min Thinzar, Barry Jonathan, Stephens Jeffrey W
Diabetes Centre, Morriston Hospital, Swansea Bay University Health Board, Swansea, SA6 6NL UK.
Diabetes Centre, Singleton Hospital, Swansea Bay University Health Board, Swansea, UK.
J Diabetes Metab Disord. 2023 Sep 24;22(2):1763-1768. doi: 10.1007/s40200-023-01311-4. eCollection 2023 Dec.
Bariatric surgery is well-established to support long-term metabolic health benefits associated with considerable weight loss. Here, we aim to determine the longer-term impact of bariatric surgery on liver enzymes and associations with other metabolic improvements.
One hundred patients who underwent bariatric surgery between 2007 and 2014 were included, and changes in liver enzymes, anthropometric measures and other parameters were observed over a mean 9.8 years.
At the time of surgery, the mean age was 45.4 ± 9.6 years, weight 141.2 ± 31.6 kg, and body mass index (BMI) 50.2 ± 10.1 kg/m. Most patients underwent sleeve gastrectomy [n = 71] with a mean follow-up duration 9.8 ± 2.3 years. From baseline, alanine transaminase (ALT) reduced by 41.3% within 12 months post-operatively (36.6 ± 29.2 U/L to 21.5 ± 14.9 U/L, p < 0.001), which was sustained at recent follow-up (20.2 ± 10.7 U/L, p < 0.001). There were associated reductions in body weight, BMI, HbA1c, blood pressure and triglycerides. Patients with greater baseline ALT had the greatest reduction in ALT over follow-up.
Bariatric surgery is associated with rapid and sustained improvements in routine liver enzymes at 10 years, and sustained improvements in features of the metabolic syndrome.
The online version contains supplementary material available at 10.1007/s40200-023-01311-4.
减重手术已被充分证实有助于实现与显著体重减轻相关的长期代谢健康益处。在此，我们旨在确定减重手术对肝脏酶的长期影响以及与其他代谢改善的关联。
纳入了2007年至2014年间接受减重手术的100名患者，并在平均9.8年的时间里观察了肝脏酶、人体测量指标和其他参数的变化。
手术时，平均年龄为45.4±9.6岁，体重为141.2±31.6千克，体重指数（BMI）为50.2±10.1千克/米²。大多数患者接受了袖状胃切除术[n = 71]，平均随访时间为9.8±2.3年。与基线相比，术后12个月内丙氨酸转氨酶（ALT）降低了41.3%（从36.6±29.2 U/L降至21.5±14.9 U/L，p < 0.001），在最近的随访中仍保持这一水平（20.2±10.7 U/L，p < 0.001）。体重、BMI、糖化血红蛋白、血压和甘油三酯也相应降低。基线ALT水平较高的患者在随访期间ALT降低幅度最大。
减重手术与10年内常规肝脏酶的快速且持续改善以及代谢综合征特征的持续改善相关。
在线版本包含可在10.1007/s40200-023-01311-4获取的补充材料。
